Stock listing

CSE:SONA Sona Nanotech, Inc. Stock

Home listing (CSE) of Sona Nanotech, Inc.

Follow Sona Nanotech, Inc. into a list and get an email when it puts out news.

Share price · CSE:SONA

$0.255 CAD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -52.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.255 – $0.260 CADNov 20, 2026
Volume
29,491 sharesNov 20, 2026
Market cap
$31.31M CADAt the close on Nov 20, 2026 · price × 122.8M shares outstanding
52-week range
$0.240 – $0.600 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13,549 CADMedian day 21,998 shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sona Nanotech, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
CSE:SONA · Home$0.255 CAD0.000 (0.0%)29,491$0.260$0.260$0.255$0.255Close on Nov 20, 2026
OTC:SNANF$0.197 USD+0.015 (+8.3%)850$0.197$0.197$0.197$0.182Close on Nov 13, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:SONA · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.2550.0000.0%$0.260$0.260$0.25529,491
$0.255+0.005+2.0%$0.260$0.270$0.25517,900
$0.250-0.010-3.8%$0.260$0.270$0.2409,897
$0.260-0.010-3.7%$0.275$0.275$0.2605,454
$0.270+0.020+8.0%$0.260$0.270$0.26012,129
$0.250-0.030-10.7%$0.260$0.260$0.25068,320
$0.2800.0000.0%$0.280$0.280$0.2800
$0.2800.0000.0%$0.285$0.285$0.2808,100
$0.280-0.015-5.1%$0.265$0.280$0.26083,181
$0.295-0.005-1.7%$0.295$0.295$0.295645
$0.300+0.015+5.3%$0.285$0.300$0.27556,602
$0.2850.0000.0%$0.285$0.285$0.280120,306
$0.2850.0000.0%$0.285$0.285$0.270131,576
$0.285+0.005+1.8%$0.285$0.285$0.27010,723
$0.2800.0000.0%$0.285$0.285$0.28026,130
$0.2800.0000.0%$0.280$0.280$0.2800
$0.280+0.005+1.8%$0.265$0.285$0.26513,572
$0.275+0.015+5.8%$0.265$0.285$0.26097,032
$0.260-0.025-8.8%$0.270$0.270$0.26049,472
$0.285+0.020+7.5%$0.280$0.285$0.28017,624
$0.265-0.025-8.6%$0.290$0.290$0.260164,844
$0.290+0.010+3.6%$0.290$0.295$0.2909,500
$0.2800.0000.0%$0.310$0.310$0.28051,015
$0.280-0.040-12.5%$0.320$0.320$0.28092,900
$0.320-0.005-1.5%$0.325$0.330$0.31063,822
$0.325+0.020+6.6%$0.310$0.335$0.300343,020
$0.305-0.015-4.7%$0.325$0.325$0.300103,218
$0.320+0.020+6.7%$0.310$0.320$0.31037,330
$0.300-0.015-4.8%$0.330$0.330$0.30022,756
$0.315-0.015-4.5%$0.315$0.320$0.31579,100
$0.330+0.005+1.5%$0.340$0.340$0.31518,112
$0.3250.0000.0%$0.325$0.330$0.3255,150
$0.325-0.005-1.5%$0.330$0.330$0.3255,629
$0.3300.0000.0%$0.330$0.330$0.3301,704
$0.330+0.030+10.0%$0.330$0.345$0.31063,765
$0.300-0.030-9.1%$0.340$0.340$0.300106,175
$0.3300.0000.0%$0.330$0.330$0.3300
$0.330-0.005-1.5%$0.360$0.360$0.3301,630
$0.335-0.020-5.6%$0.370$0.370$0.33511,812
$0.3550.0000.0%$0.355$0.365$0.35536,800
$0.355-0.020-5.3%$0.365$0.365$0.35510,500
$0.375+0.020+5.6%$0.370$0.375$0.3708,500
$0.3550.0000.0%$0.355$0.355$0.3552,047
$0.355+0.005+1.4%$0.355$0.355$0.3552,073
$0.350-0.010-2.8%$0.350$0.350$0.3503,551
$0.360+0.010+2.9%$0.360$0.370$0.36062,705
$0.3500.0000.0%$0.360$0.370$0.35068,750
$0.350+0.005+1.4%$0.360$0.360$0.34577,822
$0.345-0.010-2.8%$0.365$0.365$0.34549,140
$0.355+0.005+1.4%$0.370$0.370$0.3551,418
$0.350-0.010-2.8%$0.375$0.375$0.35043,794
$0.360-0.020-5.3%$0.380$0.380$0.36017,065
$0.380+0.015+4.1%$0.370$0.380$0.37057,200
$0.365+0.005+1.4%$0.360$0.365$0.3605,001
$0.3600.0000.0%$0.355$0.365$0.35521,240
$0.360+0.015+4.3%$0.345$0.360$0.34517,474
$0.345+0.010+3.0%$0.365$0.365$0.34538,100
$0.335-0.025-6.9%$0.365$0.365$0.330102,703
$0.360+0.005+1.4%$0.360$0.365$0.35510,000
$0.355+0.005+1.4%$0.355$0.365$0.35040,830
$0.3500.0000.0%$0.350$0.350$0.3501,500
$0.350-0.005-1.4%$0.350$0.355$0.35013,525
$0.355+0.005+1.4%$0.355$0.355$0.34576,700
$0.3500.0000.0%$0.365$0.365$0.33571,913
Ticker
CSE:SONA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
CSE
Currency
CAD

What changed lately

Latest news

All Sona Nanotech, Inc. news

Sona Nanotech, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 45 in all · newest Oct 13, 2026 · oldest 2023
Decks
17 decks · latest September 2026

Where Sona Nanotech, Inc. is listed

ListingExchangeCountryCurrency
CSE:SONA · Home listing · This pageCSECanadaCAD
Cboe Canada:SONACboe CanadaCanadaCAD
OTC:SNANFOTCUnited StatesUSD

Cash and shares

Sep 16, 2026 · Sona Nanotech — Investor Presentation (September 2026)

Shares outstanding
122.8 million

The slide these figures come from

Valuation

Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
$31.64M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
0.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sona Nanotech, Inc. · CSE:SONAUS$21.84MUS$22.06Mn/an/an/an/an/an/a0.47
BioNxt Solutions Inc · CSE:BNXTUS$22.78MUS$22.72Mn/an/an/an/an/an/a0.22
Polyrizon Ltd. · NASDAQ:PLRZUS$22.61MUS$7.56Mn/an/an/a0.9×n/a0.0×0.67
ME Therapeutics Holdings, Inc. · CSE:METXUS$22.25MUS$21.88Mn/an/an/a49.5×n/a0.0×0.52
CervoMed Inc. · NASDAQ:CRVOUS$22.09MUS$2.49Mn/a285×n/a1.3×n/a0.0×1.97
Mendus AB · OMXSTO:IMMUUS$21.76MUS$17.65Mn/an/an/a0.4×n/a0.0×n/a
Metagenomi Therapeutics, Inc. · NASDAQ:MGXUS$21.36M−US$44.10Mn/a−6.2×n/a0.2×n/a0.4×1.65
NanoGroup SA · GPW:NNGUS$21.32MUS$18.78Mn/an/an/a4.0×n/a0.0×n/a
Cel-Sci Corporation · AMEX:CVMUS$21.28MUS$14.76Mn/an/an/a1.9×n/a0.0×1.13
ZYUS Life Sciences Corporation · TSXV:ZYUSUS$20.92MUS$25.65Mn/a98.4×n/an/an/an/a-0.02
Xbrane Biopharma AB · OMXSTO:XBRANEUS$20.88MUS$23.48Mn/a1.9×n/a0.4×−49.0%0.1×n/a
Median of the othersUS$21.56MUS$18.22M50.1×1.1×−49.0%0.0×0.67

Team and board

Officers

OfficerRole
David ReganCEO
Robert RandallChief Financial Officer
Greg YoungVP Corporate Services
Fiona MarshallManager
Gerry MarangoniCo-Founder
Kulbir SinghCo-Founder & Chief Technology Officer

Board

DirectorRole
Mark LievonenChair
Gerry MarangoniCo-Founder
James MegannDirector
Jonathan TritesBoard-certified Specialist
Len PagliaroDirector
Michael A. FlemingDirector
Neil FraserDirector
Walter StrappsDirector
Wayne MylesDirector

Events

QuarterResultsShare move
Q3 2025Sep 29, 2025 · After close0.0%
Q2 2025Jun 26, 2025 · After close+8.7%
Quarter to Jan 31, 2021Mar 1, 2021 · After close−11.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck24 slidesSeptember 2026
Investor Presentation (May 2026)Investor deck28 slidesMay 2026
Investor Presentation (October 2025)Investor deck23 slidesOctober 2025
Investor Presentation (May 2025)Investor deck26 slidesMay 2025
Investor Presentation (March 2025)Investor deck26 slidesMarch 2025
Investor Presentation (August 2024)Investor deck24 slidesAugust 2024
Investor Presentation (July 2024)Investor deck21 slidesJuly 2024
Investor Presentation (May 2024)Investor deck26 slidesMay 2024
Investor Presentation (April 2024)Investor deck23 slidesApr 12, 2024
Investor Presentation (April 2024)Investor deck21 slidesApr 12, 2024
All 17 decks
DeckKindSlidesDate
Investor Presentation (November 2023)Investor deck23 slidesNovember 2023
Investor Presentation (September 2023)Investor deck24 slidesSeptember 2023
Investor Presentation (January 2023)Investor deck21 slidesJanuary 2023
Shareholder Meeting (April 2021)Shareholder meeting19 slidesApril 2021
Investor Presentation (November 2020)Investor deck20 slidesNovember 2020
Investor Presentation (November 2020)Investor deck22 slidesNovember 2020
Investor Presentation (May 2020)Investor deck13 slidesMay 2020

Open Decks

Financings

RaiseDateIn US dollars
Private placement of common shares
Announced: up to C$2.4M · C$0.3 a share
Insiders: Insiders and certain other existing shareholders may also subscribe for Shares
Use of proceeds: Studies and R&D to advance its Targeted Hyperthermia Therapy oncology treatment toward the clinic, and general working capital
Jul 31, 2026US$1.71M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue000
Gross profit000
Research and development847.0K277.9K455.3K70.9K154.1K3.61M51.9K136.1K55.6K34.3K
Selling, general and administrative1.75M1.91M1.93M3.21M10.5M5.51M1.63M5.06M357.3K509.4K
Operating income-3.44M-2.92M-2.62M-2.73M-10.7M-9.13M-1.66M-5.18M-357.7K-591.5K
Depreciation and amortization720.0K14.0K36.8K60.3K65.6K66.4K51.1K27.8K3.80K795
EBITDA-2.72M-2.90M-2.58M-2.67M-10.7M-9.06M-1.60M-5.15M-353.9K-590.7K
Interest expense38.6K4.13K13.1K5.27K20.8K25.6K145.6K75.6K00
Income before tax-3.25M-2.70M-2.50M-2.36M-10.4M-6.27M-2.52M-5.20M-2.28M-642.8K
Income tax000
Net income-3.25M-2.70M-2.50M-2.36M-10.4M-6.27M-2.52M-5.20M-2.28M-642.8K
Earnings per share, basic-0.03-0.02-0.03-0.03-0.16-0.10-0.04-0.10-0.03

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents122.0K1.85M109.4K155.4K1.18M102.8K580.7K1.80M428.9K19.0K
Short-term investments4.00K4.00K6.00K9.00K13.0K8.00K4.50K5.50K355.6K561.4K
Receivables105.0K97.2K54.5K252.8K132.8K61.8K16.0K277.0K141.0K95.7K
Current assets298.6K2.00M263.3K470.0K1.41M548.0K618.0K2.10M315.8K142.9K
Property, plant and equipment014.0K50.7K111.1K176.7K241.2K1.08M20.3K590
Total assets1.33M3.75M2.75M520.8K1.52M724.6K859.2K3.18M1.74M4.85M
Accounts payable906.9K647.3K900.8K331.7K576.0K2.07M417.2K727.5K238.0K551.3K
Current liabilities1.06M842.3K1.06M420.2K2.05M4.16M1.21M2.44M962.0K664.8K
Long-term debt307.7K394.7K527.7K608.5K700.8K0666.8K543.2K172.3K380.7K
Total debt1.16M962.6K334.6K
Total liabilities1.37M1.24M1.59M1.03M2.75M4.16M1.88M2.98M1.71M2.17M
Shareholders' equity-38.8K2.51M1.16M-507.9K-1.22M-3.44M-1.02M199.1K24.5K2.68M
Shares outstanding112.9M111.7M95.1M69.0M65.2M61.3M57.7M53.5M88.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.96M-1.96M-1.26M-1.81M-3.81M-4.05M-1.36M-1.55M-244.2K-328.1K
Capital spending00000-376.6K-158.7K-145.7K-23.5K-651
Free cash flow-1.96M-1.96M-1.26M-1.81M-3.81M-4.75M-1.52M-1.54M-175.8K-328.8K
Cash from investing014.6K0-694.0K-158.7K-145.7K-23.5K-651
Cash from financing228.4K3.70M1.20M777.6K4.89M4.27M298.6K3.33M395.8K336.5K
Share buybacks3.70M1.01M585.1K4.34M264.7K41.3K2.44M260.0K
Change in cash-1.73M1.75M-46.0K-1.03M1.08M-477.9K-1.22M1.63M128.1K7.75K

Open Financials

Cap table

Built by 6ix from Sona Nanotech, Inc.’s releases · as of Oct 13, 2026

Common shares
122,798,625
Fully diluted
125,173,625

Fully diluted

LineSharesAs of
Common shares122,798,625Jul 31, 2026
Options and RSUs2,375,000Oct 13, 2026

Warrants and options

Lot
Stock options · C$0.35 · expire about Oct 2031

Share count over time

CountShares
Nov 22, 2026122,798,625
Jul 31, 2026114,375,253

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
R Wayne Myles
Director of Issuer
Buy133,333CAD 0.29CAD 39,333Aug 10, 2026
Walter Strapps
Director of Issuer
Buy166,666CAD 0.29CAD 49,166Aug 10, 2026
David A Regan
Senior Officer of Issuer
Buy17,500CAD 0.32CAD 5,600Mar 19, 2026
David A Regan
Senior Officer of Issuer
Buy25,000CAD 0.46CAD 11,500Jan 2, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David ReganCEO · Since at least Sep 11, 2026
Fiona MarshallManager · Since at least Nov 4, 2026
Gerry MarangoniCo-Founder · Since at least Nov 4, 2026
Greg YoungVP Corporate Services · Since at least Sep 11, 2026
James MegannDirector · Since at least Nov 5, 2026
Jonathan TritesBoard-certified Specialist · Since at least Apr 16, 2026
Kulbir SinghCo-Founder & Chief Technology Officer · Since at least Oct 13, 2026
Len PagliaroDirector · Since at least Oct 20, 2025
Mark LievonenChair · Since at least Jun 11, 2026
Michael A. FlemingDirector · Since at least Jun 11, 2026
All 14 people
PersonSeat
Neil FraserDirector · Since at least Nov 5, 2026
Robert RandallChief Financial Officer · Since at least Nov 5, 2026
Walter StrappsDirector · Since at least Nov 5, 2026
Wayne MylesDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Sona Nanotech, Inc.